Cite
6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407.
MLA
Cheng, Y., et al. “6P Pembrolizumab plus Chemotherapy vs Chemotherapy in Asian Patients with PD-L1 Negative Advanced NSCLC: Pooled Analysis of KN021G, KN189 and KN407.” Annals of Oncology, vol. 32, Dec. 2021, pp. S1376–77. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.10.022.
APA
Cheng, Y., Yang, J. .-H., Okamoto, I., Zhang, L., Hu, J., Wang, D., Hu, C., Zhou, J., Wu, L., Cao, L., Liu, J., Zhang, H., Sun, H., Wang, Z., Gao, H., Yan, Y., Xiao, S., Lin, J., Pietanza, M. C., & Kurata, T. (2021). 6P Pembrolizumab plus chemotherapy vs chemotherapy in Asian patients with PD-L1 negative advanced NSCLC: Pooled analysis of KN021G, KN189 and KN407. Annals of Oncology, 32, S1376–S1377. https://doi.org/10.1016/j.annonc.2021.10.022
Chicago
Cheng, Y., J.C-H. Yang, I. Okamoto, L. Zhang, J. Hu, D. Wang, C. Hu, et al. 2021. “6P Pembrolizumab plus Chemotherapy vs Chemotherapy in Asian Patients with PD-L1 Negative Advanced NSCLC: Pooled Analysis of KN021G, KN189 and KN407.” Annals of Oncology 32 (December): S1376–77. doi:10.1016/j.annonc.2021.10.022.